• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock (NY:ATNM)

1.870 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EDT, Jul 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 120
Open 1.870
Bid (Size) 1.800 (1)
Ask (Size) 1.870 (9)
Prev. Close 1.870
Today's Range 1.870 - 1.870
52wk Range 1.029 - 8.640
Shares Outstanding 21,331,314
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
May 27, 2025
From Faruqi & Faruqi, LLP
Via Business Wire
ATNM Deadline: Rosen Law Firm Urges Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
May 23, 2025
From Rosen Law Firm
Via Business Wire

Performance

YTD
+48.4%
+48.4%
1 Month
+23.0%
+23.0%
3 Month
+43.8%
+43.8%
6 Month
+41.7%
+41.7%
1 Year
-76.6%
-76.6%

More News

Read More
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Ultra Clean, and SoundHound and Encourages Investors to Contact the Firm
May 21, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and SoundHound and Encourages Investors to Contact the Firm
May 14, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
May 14, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
May 13, 2025
From Pomerantz LLP
Via GlobeNewswire
Faruqi & Faruqi Reminds Actinium Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 26, 2025 - ATNM
May 11, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
May 09, 2025
From Pomerantz LLP
Via GlobeNewswire
ATNM INVESTOR ALERT: Kirby McInerney LLP Reminds Actinium Pharmaceuticals, Inc. Investors of Looming Lead Plaintiff Deadline in Class Action Lawsuit
May 08, 2025
From Kirby McInerney LLP
Via Business Wire
ATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
April 29, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
April 29, 2025
From Pomerantz LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and Cerevel and Encourages Investors to Contact the Firm
April 28, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
April 26, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire
ROSEN, A LEADING LAW FIRM, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ATNM
April 25, 2025
From The Rosen Law Firm PA
Via GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
April 23, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and Cerevel and Encourages Investors to Contact the Firm
April 21, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
April 20, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
April 17, 2025
From Pomerantz LLP
Via GlobeNewswire
ATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
April 16, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Solaris, Actinium, Bakkt, and Cerevel and Encourages Investors to Contact the Firm
April 15, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
ATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
April 13, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium
April 09, 2025
From Faruqi & Faruqi LLP
Via GlobeNewswire
Shareholder Alert: Scott+Scott Attorneys at Law LLP Issues Corrected Notice to Clarify Deadline To Seek Appointment As Lead Plaintiff In Securities Class Action Against Actinium Pharmaceuticals, Inc. (NYSE American: ATNM)
April 08, 2025
From Scott+Scott Attorneys at Law LLP
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
April 07, 2025
From Pomerantz LLP
Via GlobeNewswire
ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
April 02, 2025
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire

Frequently Asked Questions

Is Actinium Pharmaceuticals, Inc. (Delaware) Common Stock publicly traded?
Yes, Actinium Pharmaceuticals, Inc. (Delaware) Common Stock is publicly traded.
What exchange does Actinium Pharmaceuticals, Inc. (Delaware) Common Stock trade on?
Actinium Pharmaceuticals, Inc. (Delaware) Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Actinium Pharmaceuticals, Inc. (Delaware) Common Stock?
The ticker symbol for Actinium Pharmaceuticals, Inc. (Delaware) Common Stock is ATNM on the New York Stock Exchange
What is the current price of Actinium Pharmaceuticals, Inc. (Delaware) Common Stock?
The current price of Actinium Pharmaceuticals, Inc. (Delaware) Common Stock is 1.870
When was Actinium Pharmaceuticals, Inc. (Delaware) Common Stock last traded?
The last trade of Actinium Pharmaceuticals, Inc. (Delaware) Common Stock was at 07/23/25 08:00 PM ET
What is the market capitalization of Actinium Pharmaceuticals, Inc. (Delaware) Common Stock?
The market capitalization of Actinium Pharmaceuticals, Inc. (Delaware) Common Stock is 39.89M
How many shares of Actinium Pharmaceuticals, Inc. (Delaware) Common Stock are outstanding?
Actinium Pharmaceuticals, Inc. (Delaware) Common Stock has 40M shares outstanding.
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap